AesRx is a biopharmaceutical company dedicated to the development of two novel drugs, each of which targets an orphan disease.
AesRx’s lead program, Aes-103, is a potential breakthrough in the treatment of sickle cell disease. AesRx has commenced clinical trials of Aes-103 in a collaboration with the NIH.
AesRx’s second development program, Aes-210, is targeted to treat certain inflammatory diseases of the lower intestine, including distal ulcerative colitis, pouchitis and radiation induced proctitis. Aes-210 is in Phase 2.